NASDAQ
Rhythm Pharmaceuticals, Inc. (RYTM)
♥ 524 Thanks from members
Rhythm Pharmaceuticals displays robust commercial and clinical momentum driven by expanding IMCIVREE approvals in acquired hypothalamic obesity and a scalable MC4R franchise, attracting high-profile institutional backing despite ongoing operational losses.